{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:34:29Z","timestamp":1740180869253,"version":"3.37.3"},"reference-count":22,"publisher":"Consilium Medicum","issue":"7","license":[{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Aim. To evaluate the effect of Sacubitril\/Valsartan (S\/V) on the functional status, systolic and diastolic function of the left ventricle (LV), tolerability of therapy and to determine predictors of its effectiveness in patients with cancer therapy-related heart failure (\u0421TRHF).\r\nMaterials and methods. Forty patients 58 [46; 65.5] years of age with HF associated with anthracycline-containing cancer therapy were enrolled. Clinical examination, echocardiography, and assessment of potassium and creatinine levels were performed at baseline and after 6 months of S\/V therapy.\r\nResults. NYHA functional class (FC) improvement was observed in 22 (64.7%) patients. Radiation therapy (RT) decreased (OR 0.091; 95% CI 0.010.83; p=0.03) while baseline low LV EF increased (OR 9.0; 95% CI 1.7845.33; p=0.008) the odds of FC improvement. LV EF increased from 37.3 [30; 42.5] % to 45 [38; 48] % (p0.0001) and exceeded 50% in 7 (20.6%) patients. The odds of LV EF recovery increased when S\/V therapy was initiated 1 year after anthracycline therapy (OR 10.67; 95% CI 1.5772.67; p=0.0016) and decreased in patients with the history of RT (OR 0.14; 95% CI 0.020.89; p=0.0037) and in patients over 58 years (OR 0.07; 95% CI 0.010.68; p=0.022). LV diastolic function improvement included E\/e descent from 13.6 [10; 18.3] to 8.9 [6.9; 13.7] (p=0.0005), and decrease in diastolic dysfunction grade in 18 (45%) patients (p=0.0001). No significant change in serum potassium (4.45 [4.2; 4.8] versus 4.5 [4.3; 4.8]; p=0.5) and creatinine (75.4 [67.6; 85.1] versus 75.5 [68.2; 98.3]; p=0.08) levels were observed.\r\nConclusion. S\/V therapy is associated with improvement of EF, systolic and diastolic LV function, demonstrates a favorable tolerability profile in patients with \u0421TRHF. Lack of RT and low baseline LV EF increased the odds of LV EF improvement; lack of RT, early (1 year) start of treatment after discontinuation of anthracycline therapy, and age 58 years increased the odds of LV EF recovery.<\/jats:p>","DOI":"10.26442\/00403660.2023.07.202281","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T03:18:23Z","timestamp":1695957503000},"page":"560-567","source":"Crossref","is-referenced-by-count":1,"title":["Effects of sacubitril\/valsartan in patients with cancer therapy-related heart failure"],"prefix":"10.26442","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1996-3416","authenticated-orcid":false,"given":"Marina V.","family":"Vitsenya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9290-9884","authenticated-orcid":false,"given":"Alexandra V.","family":"Potekhina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8159-7948","authenticated-orcid":false,"given":"Svetlana V.","family":"Gavryushina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nursiiat M.","family":"Ibragimova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8377-2388","authenticated-orcid":false,"given":"Olga V.","family":"Stukalova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3280-3521","authenticated-orcid":false,"given":"Valery P.","family":"Masenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1993-9264","authenticated-orcid":false,"given":"Tatiana V.","family":"Sharf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4369-1393","authenticated-orcid":false,"given":"Fail T.","family":"Ageev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","published-online":{"date-parts":[[2023,9,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"ref2","unstructured":"\u0420\u043e\u0441\u0441\u0442\u0430\u0442. \u0417\u0434\u0440\u0430\u0432\u043e\u043e\u0445\u0440\u0430\u043d\u0435\u043d\u0438\u0435. \u0420\u0435\u0436\u0438\u043c \u0434\u043e\u0441\u0442\u0443\u043f\u0430: https:\/\/rosstat.gov.ru\/folder\/13721. \u0421\u0441\u044b\u043b\u043a\u0430 \u0430\u043a\u0442\u0438\u0432\u043d\u0430 \u043d\u0430 03.05.2023 [Federal State Statistics Service. Health care. Available at: https:\/\/rosstat.gov.ru\/folder\/13721. Accessed: 03.05.2023 (in Russian)]."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2015.133"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2017.1344099"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw211"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.03.095"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013777"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-020-00078-4"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12627"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-021-00121-y"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004133421502"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2018-313234"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2002.3282"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.129"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00039"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2010.09.048"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077"},{"key":"ref20","unstructured":"\u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438. \u0425\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u0441\u0435\u0440\u0434\u0435\u0447\u043d\u0430\u044f \u043d\u0435\u0434\u043e\u0441\u0442\u0430\u0442\u043e\u0447\u043d\u043e\u0441\u0442\u044c. \u0420\u0443\u0431\u0440\u0438\u043a\u0430\u0442\u043e\u0440 \u041a\u0420. \u0420\u0435\u0436\u0438\u043c \u0434\u043e\u0441\u0442\u0443\u043f\u0430: https:\/\/cr.minzdrav.gov.ru\/schema\/156_1. \u0421\u0441\u044b\u043b\u043a\u0430 \u0430\u043a\u0442\u0438\u0432\u043d\u0430 \u043d\u0430 03.05.2023 [Clinical recommendations of the Ministry of Health of the Russian Federation. Chronic heart failure. Available at: https:\/\/cr.minzdrav.gov.ru\/schema\/156_1. Accessed: 03.05.2023 (in Russian)]."},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Canu A, Maurin V, Dos Santos P, Picard F. Results of a single center experience on 200 consecutive patients treated with Entresto (sacubitril\/valsartan). Eur J Heart Fail. 2017;19(Suppl. 1):413.","DOI":"10.1016\/S1878-6480(17)30123-4"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2022.04.013"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/595927\/135401","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/595927\/135401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T03:18:35Z","timestamp":1695957515000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/595927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,9,29]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2023.07.202281","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"type":"electronic","value":"2309-5342"},{"type":"print","value":"0040-3660"}],"subject":[],"published":{"date-parts":[[2023,9,29]]}}}